Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16824
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGibson, Peter G-
dc.contributor.authorReddel, H-
dc.contributor.authorMcDonald, VM-
dc.contributor.authorMarks, G-
dc.contributor.authorJenkins, C-
dc.contributor.authorGillman, A-
dc.contributor.authorUpham, J-
dc.contributor.authorSutherland, Michael-
dc.contributor.authorRimmer, J-
dc.contributor.authorThien, F-
dc.contributor.authorKatsoulotos, GP-
dc.contributor.authorCook, M-
dc.contributor.authorYang, I-
dc.contributor.authorKatelaris, C-
dc.contributor.authorBowler, S-
dc.contributor.authorLangton, D-
dc.contributor.authorRobinson, P-
dc.contributor.authorWright, C-
dc.contributor.authorYozghatlian, V-
dc.contributor.authorBurgess, S-
dc.contributor.authorSivakumaran, P-
dc.contributor.authorJaffe, A-
dc.contributor.authorBowden, J-
dc.contributor.authorWark, PAB-
dc.contributor.authorYan, KY-
dc.contributor.authorKritikos, V-
dc.contributor.authorPeters, M-
dc.contributor.authorHew, M-
dc.contributor.authorAminazad, A-
dc.contributor.authorBint, M-
dc.contributor.authorGuo, M-
dc.date.accessioned2017-08-31T05:36:05Z-
dc.date.available2017-08-31T05:36:05Z-
dc.date.issued2016-09-
dc.identifier.citationInternal Medicine Journal 2016; 46(9): 1054-1062en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16824-
dc.description.abstractBACKGROUND: Severe asthma is a high impact disease. Omalizumab targets the allergic inflammatory pathway; however, effectiveness data in a population with significant comorbidities are limited. AIMS: To describe severe allergic asthma, omalizumab treatment outcomes and predictors of response among the Australian Xolair Registry participants. METHODS: A web-based post-marketing surveillance registry was established to characterise the use, effectiveness and adverse effects of omalizumab (Xolair) for severe allergic asthma. RESULTS: Participants (n = 192) (mean age 51 years, 118 female) with severe allergic asthma from 21 clinics in Australia were assessed, and 180 received omalizumab therapy. They had poor asthma control (Asthma Control Questionnaire, ACQ-5, mean score 3.56) and significant quality of life impairment (Asthma-related Quality of Life Questionnaire score 3.57), and 52% were using daily oral corticosteroid (OCS). Overall, 95% had one or more comorbidities (rhinitis 48%, obesity 45%, cardiovascular disease 23%). The omalizumab responder rate, assessed by an improvement of at least 0.5 in ACQ-5, was high at 83%. OCS use was significantly reduced. The response in participants with comorbid obesity and cardiovascular disease was similar to those without these conditions. Baseline ACQ-5 ≥ 2.0 (P = 0.002) and older age (P = 0.05) predicted the magnitude of change in ACQ-5 in response to omalizumab. Drug-related adverse events included anaphylactoid reactions (n = 4), headache (n = 2) and chest pains (n = 1). CONCLUSION: Australian patients with severe allergic asthma report a high disease burden and have extensive comorbidity. Symptomatic response to omalizumab was high despite significant comorbid disease. Omalizumab is an effective targeted therapy for severe allergic asthma with comorbidity in a real-life setting.en_US
dc.subjectAllergyen_US
dc.subjectComorbidityen_US
dc.subjectOmalizumaben_US
dc.subjectPhenotypeen_US
dc.subjectRegistryen_US
dc.subjectSevere asthmaen_US
dc.titleEffectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registryen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternal Medicine Journalen_US
dc.identifier.affiliationCentre for Healthy Lungs, Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationUniversity of Sydney, Liverpool Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationSchool of Nursing and Midwifery, University of Newcastle, Newcastle, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Liverpool Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Thoracic Medicine, Concord Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSt Vincent's Clinic, Campbelltown Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Box Hill Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSt George Specialist Centre, Campbelltown Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Immunology, Canberra Hospital, Canberra, Australian Capital Territory, Australiaen_US
dc.identifier.affiliationDepartment of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Campbelltown Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Mater Adult Hospital, Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationDepartment of Thoracic Medicine, Frankston Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Children's Hospital at Westmead, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Nambour Hospital, Nambour, Queensland, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, St George Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationQLD Children's Lung and Sleep Specialists, Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Gold Coast District Hospital, Gold Coast, Queensland, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Sydney Children's Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory, Allergy and Sleep Medicine, Flinders Medical Centre, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationClinical Management, Woolcock Institute of Medical Research, Sydney, New South Wales, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27350385en_US
dc.identifier.doi10.1111/imj.13166en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Feb 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.